#155 Dutch biotech startup is looking for Israeli partners to co-develop cannabis-based pharmaceutical products.
- Industry Life sciences and health
- Online since 2022-02-01
Stabican, a Dutch biotech start-up company, is looking for Israeli partners to co-develop cannabis-based pharmaceutical products using their proprietary pharmaceutical ingredient technology platform.
Stabican offers pharmaceutical companies a solution to current shelf-life stability-, bioavailability-, solubility- and processing problems of fat-soluble molecules (e.g. full-spectrum cannabis extracts, isolates, vitamin A, D, H, K, nicotine, psilocin). Stabican's proprietary Active Pharmaceutical Ingredient Powder meets all the quality standards of the pharmaceutical industry and at the same time makes strong IP-protection of the API and the final drug possible.
The cannabis-based API’s can be used in a wide range of applications including sustained release oral solid dosage forms, semisolid, dry-powder inhalers (DPI), liquid formulations, E-liquids and transdermal applications. With the knowledge of the company's experienced team, it is possible to adapt the product platform to the needs of partners in First-In-Human studies.
Contact person: Ivo Schefman, [email protected]
Go to website